COVID-19疫情期间痴呆患者抗精神病药处方率变化
这项跨国网络队列研究使用6国8个数据库的电子健康记录和理赔数据,纳入2016年1月至2021年11月65岁及以上痴呆患者。研究发现疫情初期多个数据库痴呆发病率下降,但6个数据库显示抗精神病药处方率上升,且2021年仍维持高位,提示疫情 disrupt 了痴呆照护。
要点
- 疫情初期7个数据库痴呆发病率下降,最显著为美国某数据库RR 0.30(95%CI 0.27-0.32)。
- 6个数据库抗精神病药处方率上升,2020年5月韩国某数据库RR 2.11(95%CI 1.47-3.02)。
- 中断时间序列显示意大利和美国Medicare数据库在限制措施后处方率立即上升。
核心结论
- 6国研究一致表明疫情初期痴呆患者抗精神病药处方率上升,急性期后未降至疫情前水平。
- 疫情 disrupt 了痴呆患者照护,需制定干预策略确保照护质量。
研究设计与样本
- 跨国网络队列研究,使用6国(法国、德国、意大利、韩国、英国、美国)8个数据库的电子健康记录和理赔数据。
- 暴露为2020年4月起实施的人群COVID-19限制措施,采用中断时间序列分析。
主要发现
- 疫情初期(2020年4-6月)7个数据库痴呆发病率下降,最显著为美国某数据库RR 0.30(95%CI 0.27-0.32)。
- 法国、意大利、韩国、英国和美国的总痴呆患者中抗精神病药处方人数减少。
- 6个数据库(覆盖所有国家)抗精神病药处方率上升,2020年5月韩国某数据库RR 2.11(95%CI 1.47-3.02),6月英国RR 1.96(95%CI 1.24-3.09)。
- 上述6个数据库2021年处方率仍维持高位。
- 中断时间序列显示意大利(RR 1.31;95%CI 1.08-1.58)和美国Medicare数据库(RR 1.43;95%CI 1.20-1.71)在限制措施后处方率立即上升。
关键数值与推荐
- 主要结局为各数据库痴呆诊断的年发病率和月发病率,以及痴呆患者中抗精神病药处方的患病率。
- 使用中断时间序列分析量化人群COVID-19限制措施前后处方率变化。
临床怎么用
- 临床应关注疫情等公共卫生危机期间痴呆患者抗精神病药处方可能增加的趋势。
- 需加强痴呆照护质量监测,避免不适当抗精神病药使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Concerns have been raised that the use of antipsychotic medication for people living with dementia might have increased during the COVID-19 pandemic. OBJECTIVE: To examine multinational trends in antipsychotic drug prescribing for people living with dementia before and during the COVID-19 pandemic. DESIGN, SETTING, AND PARTICIPANTS: This multinational network cohort study used electronic health records and claims data from 8 databases in 6 countries (France, Germany, Italy, South Korea, the UK, and the US) for individuals aged 65 years or older between January 1, 2016, and November 30, 2021. Two databases each were included for South Korea and the US. EXPOSURES: The introduction of population-wide COVID-19 restrictions from April 2020 to the latest available date of each database. MAIN OUTCOMES AND MEASURES: The main outcomes were yearly and monthly incidence of dementia diagnosis and prevalence of people living with dementia who were prescribed antipsychotic drugs in each database. Interrupted time series analyses were used to quantify changes in prescribing rates before and after the introduction of population-wide COVID-19 restrictions. RESULTS: A total of 857 238 people with dementia aged 65 years or older (58.0% female) were identified in 2016. Reductions in the incidence of dementia were observed in 7 databases in the early phase of the pandemic (April, May, and June 2020), with the most pronounced reduction observed in 1 of the 2 US databases (rate ratio [RR], 0.30; 95% CI, 0.27-0.32); reductions were also observed in the total number of people with dementia prescribed antipsychotic drugs in France, Italy, South Korea, the UK, and the US. Rates of antipsychotic drug prescribing for people with dementia increased in 6 databases representing all countries. Compared with the corresponding month in 2019, the most pronounced increase in 2020 was observed in May in South Korea (Kangwon National University database) (RR, 2.11; 95% CI, 1.47-3.02) and June in the UK (RR, 1.96; 95% CI, 1.24-3.09). The rates of antipsychotic drug prescribing in these 6 databases remained high in 2021. Interrupted time series analyses revealed immediate increases in the prescribing rate in Italy (RR, 1.31; 95% CI, 1.08-1.58) and in the US Medicare database (RR, 1.43; 95% CI, 1.20-1.71) after the introduction of COVID-19 restrictions. CONCLUSIONS AND RELEVANCE: This cohort study found converging evidence that the rate of antipsychotic drug prescribing to people with dementia increased in the initial months of the COVID-19 pandemic in the 6 countries studied and did not decrease to prepandemic levels after the acute phase of the pandemic had ended. These findings suggest that the pandemic disrupted the care of people living with dementia and that the development of intervention strategies is needed to ensure the quality of care.
引用
- Luo H, Lau WCY, Chai Y, et al. Rates of Antipsychotic Drug Prescribing Among People Living With Dementia During the COVID-19 Pandemic. JAMA Psychiatry. 2023. PMID: 36696128. doi:10.1001/jamapsychiatry.2022.4448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。